Search

Niosomes increase drug bioavailability and address issues with drug insolubility, instability, rapid degradation, and lower treatment costs. By incorporating herbal medications into the delivery method, niosomes are created to enhance their toxicity protection, sustained delivery, pharmacological action, tissue macrophage distributions, and resilience to chemical and physical deterioration. By limiting a drug's activity to its intended target cells, niosomes make it less toxic and raise its therapeutic index. Niosomes, a novel medication delivery method, help increase therapeutic effects while decreasing adverse effects in herbal compositions. This study's goal is to draw attention to the use of phytoniosomes. Niosomes, a new type of drug delivery vehicle, are useful in herbal formulations because they lessen toxic effects while enhancing therapeutic effects. This article reveals details regarding niosomes and the use of herbs in niosomes. To acquire the data for the aforementioned study, research and review publications from different publishers, including Hindawi, Elsevier, Springer Nature, and Bentham Science, were examined using Google Scholar as a search engine. Herbal medicines containing water-soluble phytoconstituents are less absorbed due to their large molecular mass and less lipid solubility. To overcome these drawbacks, numerous experiments are being done that try to incorporate herbal components into cutting-edge pharmaceutical delivery systems like niosomes. Improvements in stability and pharmacological activity, are also brought about by the formulation of phytoniosomes. Numerous studies employing different phytoniosome have been conducted. However, more studies are required to gauge the potency of the phytoniosome using a variety of herbs. [ABSTRACT FROM AUTHOR]

Antibodies that attack the neuromuscular junction induce myasthenia gravis, an immunological illness. Such antibodies assault and degrade postsynaptic molecules in by binding to the postsynaptic muscular end-plate. As a consequence, signal transduction is disrupted, resulting in muscular weakness and fatigability. Developments in our knowledge of the immunological mechanisms that cause myasthenia gravis have paved the way for the development of new targeted immunity treatments. The majority of myasthenia gravis sufferers have a well-managed condition with just minor to moderate symptoms. The goal must be to create more targeted therapies that reduce or enhance tolerance to the well-known and particular autoimmune reactions that result in autoantibody formation and muscular weakening. Several drugs widely used in obstetrics can aggravate the condition. The impact of maternity on myasthenia varies greatly from one woman to the next, as well as from one pregnancy to the next within the same woman. Acetylcholine esterase inhibitors, corticosteroids, and other immunosuppressants, as well as proper rest, are the most common therapy. Intrauterine antibody exposure can cause in utero or neonatal effects in newborns, which are usually temporary. This review focuses on myasthenia gravis subgroups and treatment breakthroughs, as well as the influence of myasthenia gravis on pregnancy and its management. [ABSTRACT FROM AUTHOR]